Program Focus

How We Advance Programs

We focus on undervalued or dormant assets. We identify the most value-creating path and (re)design the development plan to accelerate time to market across our therapeutic priorities.

Poor prognosis cancer
Obesity in transitional countries
Liver diseases
Organ regeneration
ME/CFS

Operationally, this focus translates into structuring deal rationales, leading negotiations, and conducting due diligence across technical, regulatory, and clinical dimensions. In parallel, we design or support the design of clinical protocols aligned with mechanism of action, target indication, and biomarker availability. Our clinical development strategy applies adaptive approaches to enable early signal detection in exploratory studies.

Scroll to Top

Poor prognosis cancers

Achieve clinically meaningful survival extension for patients with cancers of extremely poor prognosis, setting new standards beyond current therapies

 

Cancers such as pancreatic, glioblastoma, or advanced lung and biliary cancers remain largely untreatable. Most patients die within months, and existing therapies offer limited efficacy while severely impacting quality of life. Innovation has stagnated, and progress is incremental at best. Developing therapies that extend overall survival by a clinically meaningful factor versus the future standard of care delivers tangible hope where medicine has so far failed.

Obesity in Transitional Countries

Enable effective and affordable obesity treatment in transitional countries, achieving ≥20% weight reduction within one year while maintaining muscle mass and long-term health

 

Populations in transitional countries face a rapidly growing obesity and cardiovascular disease pandemic, driven by rising incomes and carb-heavy diets. Unlike developed markets, where reimbursement or disposable income supports access to treatment, these healthcare systems lack the resources for current GLP-1-based therapies. Providing scalable, accessible solutions that deliver substantial and lasting weight loss while preserving metabolic health addresses a critical public health challenge and unlocks a multi-billion market opportunity.

Liver failure

Prevent liver failure, cancer progression, and the need for transplantation, reducing individual suffering and systemic healthcare costs

 

With rising obesity and type 2 diabetes, a wave of metabolic dysfunction-associated steatohepatitis (MASH) is emerging, often overlapping with chronic viral hepatitis. Despite viral control, patients face silent fibrosis progression and increasing liver cancer risk. Healthcare systems face unsustainable treatment and transplant costs, and drug options are limited so far. Addressing this “time-bomb” represents one of the largest untapped markets in biopharma.

Organ regeneration

Enable organ replacement within one month, without lifelong immunosuppression, creating a reliable, accessible, and ethical foundation for human longevity

 

Transplantations are costly, logistically complex, and unreliable. Waiting times extend into years, undermining confidence in the system. Reducing the time to solution to one month while avoiding lifelong immunosuppression could create a new paradigm. It improves comfort, reliability, planning, and cost efficiency while eliminating societal debates over organ donation and illegal trade.

ME/CFS

Enable restoration of daily functioning for patients with persistent post viral fatigue through therapies that deliver measurable and lasting symptom relief within months rather than years


Post viral fatigue syndromes such as ME/CFS and post COVID syndrome cause profound exhaustion, cognitive impairment, and loss of independence, often persisting long after the initial infection. Despite the high disease burden and societal cost, treatment options remain absent. Leveraging existing compounds from mitochondrial, neuroinflammatory, and metabolic programs enables a rapid, translational path toward therapies that address underlying dysregulation of energy metabolism and neuroimmune balance.